Anti-PD-L1 antibody [73-10],Abcam,AB228415
Anti-PD-L1 antibody [73-10] (ab228415) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-Fr, IHC-P, IP and WB. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [73-10] (ab228415) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [73-10] (ab228415) has been confirmed by Western Blot testing in PD-L1 knockout A549 cells ( ab267054 ). Anti-PD-L1 antibody [73-10] (ab228415) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 32kDa) and is sold in 50 µL selling sizes. Conjugation-ready, carrier free format available for antibody clone 73-10 - ab226766 . Antibody clone 73-10 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 555, Alexa Fluor ® 594 ( ab237402 , ab237403 , ab274896 , ab275355 ). Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP, IHC-P, Flow Cyt (Intra), WB, ICC/IF, IHC-Fr
Platform ID
BAB917393906
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity). See full target information CD274
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.